- Home
- CRT vs NSPR Comparison
CRT vs NSPR Comparison
Compare CRT & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRT
- NSPR
- Stock Information
- Founded
- CRT 1991
- NSPR 2005
- Country
- CRT United States
- NSPR United States
- Employees
- CRT N/A
- NSPR N/A
- Industry
- CRT Oil & Gas Production
- NSPR Medical/Dental Instruments
- Sector
- CRT Energy
- NSPR Health Care
- Exchange
- CRT Nasdaq
- NSPR Nasdaq
- Market Cap
- CRT 65.1M
- NSPR 74.8M
- IPO Year
- CRT 1992
- NSPR N/A
- Fundamental
- Price
- CRT $9.58
- NSPR $2.44
- Analyst Decision
- CRT
- NSPR Strong Buy
- Analyst Count
- CRT 0
- NSPR 2
- Target Price
- CRT N/A
- NSPR $4.50
- AVG Volume (30 Days)
- CRT 19.2K
- NSPR 78.5K
- Earning Date
- CRT 01-01-0001
- NSPR 08-05-2025
- Dividend Yield
- CRT 9.32%
- NSPR N/A
- EPS Growth
- CRT N/A
- NSPR N/A
- EPS
- CRT 0.99
- NSPR N/A
- Revenue
- CRT $6,834,116.00
- NSPR $7,027,000.00
- Revenue This Year
- CRT N/A
- NSPR $4.85
- Revenue Next Year
- CRT N/A
- NSPR $113.47
- P/E Ratio
- CRT $9.58
- NSPR N/A
- Revenue Growth
- CRT N/A
- NSPR 8.49
- 52 Week Low
- CRT $8.88
- NSPR $1.99
- 52 Week High
- CRT $13.31
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- CRT 42.09
- NSPR 53.21
- Support Level
- CRT $9.49
- NSPR $2.24
- Resistance Level
- CRT $9.86
- NSPR $2.55
- Average True Range (ATR)
- CRT 0.13
- NSPR 0.14
- MACD
- CRT -0.01
- NSPR 0.01
- Stochastic Oscillator
- CRT 37.78
- NSPR 58.82
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.